In Brief

INTRODUCTION
The Foxo (Forkhead Box class O) family of transcription factors (TFs) governs processes such as cellular proliferation, apoptosis, energy metabolism, autophagy, and stress resistance in response to changes in the abundance of nutrients and growth factors (Eijkelenboom and Burgering, 2013) . Foxo proteins can act as either transcriptional activators or repressors upon their high-affinity binding to the consensus sequence 5 0 -GTAAA(T/C)AA-3 0 , known as the Daf-16 family member-binding element (Obsil and Obsilova, 2011) . In addition, Foxo factors can bind and modulate other TFs (van der Vos and Coffer, 2011).
All of these activities are altered by phosphorylation, acetylation, methylation, and ubiquitination, and these post-translational modifications influence Foxo intracellular localization, turnover, transactivation, and transcriptional specificity (Zhao et al., 2011) .
Foxo TFs, through their role in the control of cell cycle progression and apoptosis, were first described as tumor suppressor genes. Nonetheless, numerous studies have revealed that Foxo1 and Foxo3 also play fundamental roles in physiologic and pathologic immune responses (Dejean et al., 2011; Hedrick, 2009; Hedrick et al., 2012; Ouyang and Li, 2011) . Because of the similarity between their DNA-binding domains, all Foxo factors can in principle bind to related sequences and therefore should regulate the same target genes. Experiments using mice deficient for a single Foxo isoform, however, clearly demonstrate that Foxo1 and Foxo3 have independent physiological functions in the immune system, suggesting that Foxo functions could be closely linked to their distinct cell type-specific expression patterns (Dejean et al., 2011; Hedrick, 2009) .
Foxo1 is abundantly expressed in lymphoid cells, where it has been shown to regulate many features of lymphocyte homeostasis including survival, homing, and differentiation. Indeed, Foxo1 has critical functions in B cell development, homing, class-switch recombination, and somatic hypermutation (Amin and Schlissel, 2008; Dengler et al., 2008) . Foxo1 also regulates both naive and memory T cell survival and trafficking Kim et al., 2013; Ouyang et al., 2009 Ouyang et al., , 2010 , thymic regulatory T (tTreg) and peripheral regulatory T (pTreg) cell development and function (Kerdiles et al., 2010; Merkenschlager and von Boehmer, 2010; Ouyang et al., 2010 Ouyang et al., , 2012 , as well as T helper 1 (Th1), Th17, and T follicular helper (Tfh) cell differentiation (Kerdiles et al., 2010; Lainé et al., 2015; Merkenschlager and von Boehmer, 2010; Oestreich et al., 2012; Ouyang et al., 2012; Stone et al., 2015) . So far, no specific role for Foxo1 has been assigned in immune cells other than lymphocytes.
Foxo3 is the main isoform expressed in the myeloid compartment. Our previous study has shown that Foxo3 is a key suppressor of inflammatory cytokine production by dendritic cells (DCs) and macrophages . These results are consistent with a non-coding polymorphism in human FOXO3 that limits inflammatory monocyte responses resulting in milder Crohn's disease and rheumatoid arthritis but more severe malaria (Lee et al., 2013) . The role played by Foxo3 in T cells is less well defined. Using Foxo1
Foxo3
À/À mice, studies have demonstrated that Foxo1 and Foxo3 cooperatively control the development and function of Foxp3 + Treg cells (Kerdiles et al., 2010; Ouyang et al., 2010) . Others have shown that Foxo3 limits the expansion of memory CD8 + T cells during acute or chronic viral infection (Sullivan et al., 2012a (Sullivan et al., , 2012b . To date, however, the precise role of Foxo3 in effector CD4 + T cells has not been addressed.
In this study, we show that the expression of Foxo3 was increased in CD4 + T cells after activation and correlated with T cell receptor (TCR) signaling strength. To address the relevance of this upregulation, we analyzed the impact of Foxo3 deficiency on CD4 + T cell effector functions and found that Foxo3 drives Eomes-dependent differentiation of IFN-g + GM-CSF + pathogenic Th1 cells and that this pathway is needed for the development of central nervous system inflammation.
RESULTS
TCR Triggering Leads to Increased Expression of Foxo3 in CD4 + T Cells
In vivo, activated (CD62L À CD44 + ) CD4 + T cells were found to exhibit a 3-fold increase in Foxo3 expression when compared to naive (CD62L + CD44 À ) CD4 + T cells ( Figure 1A ). We therefore addressed whether CD4 + T cell activation had an impact on the expression of Foxo3. Naive CD4 + T cells were stimulated with plate-bound anti-CD3 mAbs and analyzed for Foxo3 expression. T cell receptor (TCR) triggering resulted in a dose-dependent upregulation of Foxo3 in CD4 + T cells ( Figure 1B ), with increased expression over time ( Figure 1C ), whereas CD28-induced costimulation did not influence Foxo3 expression ( Figure S1A ). A dose-dependent upregulation of Foxo3 was also recorded when OT-II CD4 + T cells were stimulated with antigen-presenting cell (APC) loaded with increasing doses of OVA 323-339 peptide, confirming that TCR-dependent signal intensity regulated Foxo3 expression in activated CD4 + T cells ( Figure S1B ). To determine key signaling events inducing Foxo3 expression upon stimulation, we next activated CD4 + T cells with anti-CD3 mAbs in the presence of a series of inhibitors that block specific pathways downstream of TCR. We found that inhibition of protein kinase C (PKCs) prevented Foxo3 upregulation whereas inhibition of ERK, p38, or JNK kinase pathways had no effect
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( Figure S1C ). In agreement, stimulation with phorbol 12-myristate 13-acetate (PMA) alone was able to induce Foxo3 expression whereas ionomycin did not ( Figure S1D ). To dissect the pathway downstream of PKC, we used inhibitors of NF-kB and the NFAT transcription factor and showed that TCR-induced Foxo3 expression was NF-kB dependent ( Figure S1E ). Taken together, these data suggest that PKCs and NF-kB pathways downstream of TCR positively regulate Foxo3 expression in CD4 + T cells. Because activation of Foxo3 was correlated with its subcellular localization, immunofluorescence staining and subcellular fractionation combined with immunoblot analysis were performed. Foxo3 was almost entirely localized in the nucleus of activated CD4 + T cells ( Figures 1D and 1E) . Altogether, our data show that TCR-dependent signal intensity correlates with Figures S2A and S2B ) and the production of IL-10 and IL-17 was undetectable (data not shown). This decreased frequency of IFN-g-and GM-CSF-positive cells was also observed when cells were stimulated with both anti-CD3 and anti-CD28 mAbs, indicating that a co-stimulatory signal was not sufficient to restore cytokine production by Foxo3-deficient cells ( Figure S2C ). In addition, a delayed and diminished expression of T-bet, the ''master regulator'' of Th1 cell differentiation (Szabo et al., 2000) , was observed in Foxo3 À/À CD4 + T cells upon TCR engagement ( Figures 2E and 2F ). Decreased IFN-g production associated with a Foxo3 deficiency was also found under Th1 cell-polarizing conditions ( Figure 2G ) whereas proliferation and survival were not affected ( Figure S2E ). Moreover, the Foxo3 deficiency not only decreased the frequency of IFN-g + cells but also impacted the overall amount of IFN-g produced on a per-cell basis, as demonstrated by the decreased MFI of IFN-g expressed by Foxo3
À/À CD4 + T cells after either 36 or 72 hr of culture ( Figure 2H ). The frequency of T-bet-expressing cells was equivalent in both Foxo3 À/À and WT CD4 + Th1 cells ( Figure 2I) ; however, Foxo3 deficiency was also associated with decreased T-bet MFI in Th1 cells ( Figure 2J ). We next assessed the ability of Foxo3 À/À CD4 + T cell to differentiate into different Th cell lineages when stimulated in polarizing conditions. We showed that Foxo3 deficiency did not impact Th2, Th17, or Foxp3 Treg cell differentiation ( Figure S3A ). In particular, Foxo3 À/À CD4 + T cells were fully able to differentiate into Foxp3 + pTreg cells induced by transforming growth factor (TGF-b) signaling ( Figure S3B ) or suboptimal TCR activation ( Figure S3C ; Li et al., 2013a) . Moreover, we showed that tTreg cells from Foxo3 À/À mice were as suppressive as WT tTreg cells ( Figure S3D ). Collectively, these results show that Foxo3 promotes TCR-induced production of IFN-g and GM-CSF and has no notable impact on Th2, Th17, or Treg cell differentiation.
Foxo3 Is Required for TCR-Induced Eomes Expression by CD4 + T Cells
To understand the molecular mechanisms whereby Foxo3 controls CD4 + T cell differentiation, unbiased analysis of genes differentially expressed in Foxo3-deficient versus Foxo3-sufficient CD4 + T cells was achieved using both resting and activated CD4 + T cells obtained after 12 or 24 hr of stimulation with anti-
CD3 mAbs. When comparing unstimulated WT and Foxo3
À/À CD4 + T cells, only five transcripts showed greater than 2-fold change, suggesting that Foxo3 plays minimal role in resting CD4 + T cells ( Figure S4A ). This number increased upon TCR engagement suggesting that Foxo3 is mainly active after TCR stimulation (FDR % 0.05) (Figures 3A and S4B) . Three main networks were impacted by Foxo3 deletion among which the ''IFN-g and IFN-g response'' was the most dysregulated pathway ( Figure 3B ). The second network was enriched for metabolic functional categories, confirming the role of Foxo3 in the regulation of cellular metabolism ( Figure S4C ). The third identified cluster was enriched in genes involved in ''immune cell trafficking,'' suggesting that Foxo3 might have a role in T cell migration and homing ( Figure S4D ). Among all dysregulated genes, Eomes was the second (T12h) and first (T24h) most suppressed gene in Foxo3 À/À CD4 + T cells.
Analyses by RT-qPCR and flow cytometry confirmed that Foxo3-deficient CD4 + T cells exhibited a decreased expression of Eomes after activation ( Figures 3C and 3D ). Although Eomes expression is lower in CD4 + T cells than in CD8 + T cells, its expression increases after activation ( Figure S4E ). Indeed, TCR-dependent signal intensity controlled Eomes expression in CD4 + T cells, and this expression was largely Foxo3 dependent ( Figure 3E ). Eomes expression by CD4 + T cells was detected after 18 hr of stimulation and rose substantially between 36 and 72 hr, correlating with the expression of Foxo3 ( Figure 3F ). We next assessed Eomes expression in other Th cell subsets. In Th1 cell-polarizing conditions, Foxo3 also controlled Eomes expression ( Figure 3G ). Nevertheless, Eomes expression is IL-12 independent ( Figure 3H ) and its expression rose between 36 and 72 hr as observed for Th0 cells ( Figure 3I ). Finally, Eomes expression was low in Th17 and Treg cells as compared to Th0 cells ( Figure S4F ). These results collectively show that Foxo3 expression is required for TCR-induced Eomes expression in CD4 + T cells.
Foxo3 Indirectly Controls Ifng and Csf2 in CD4 + T Cells through the Regulation of Eomes Expression
Because Foxo3 expression was highly increased in CD4 + T cells expressing Eomes ( Figure 4A ), we hypothesized that Foxo3 might directly control Eomes transcription. To assess this possibility, we first performed in silico analysis to identify conserved Foxo-binding sites (FBSs) in mouse and human EOMES loci. We found three putative FBSs: one (FBS1) located in the promoter of Eomes gene (chr9: 118,478,419) and the other two (FBS2 and FBS3) positioned downstream of the 3 0 UTR of Eomes (chr9: 118,487,803), in a region enriched in transcription factor binding sites that might therefore represent a putative 3 0 UTR enhancer region (p3 0 UTR-E) ( Figure 4B ). To determine whether Foxo3 can directly bind within the Eomes locus, we conducted chromatin immuno-precipitation experiments using primer sets designed to amplify regions located at each identified FBS. We found that Foxo3 could bind to the FBS1, although binding was more pronounced for FBS2 and FBS3 ( Figure 4C ).
To address whether these FBS regions are involved in the regulation of Eomes expression, we conducted luciferase reporter assays. HEK293T cells were transfected with a reporter plasmid in which a 1 Kb fragment located upstream of the human promoter region of EOMES was cloned into the pGL3-Basic vector (pEomes_luc) (Li et al., 2013b) . Cells were co-transfected with plasmids coding for different forms of V5-tagged-FOXO3: the constitutively active form of FOXO3 (FOXO3TM) (Brunet et al., 1999) , the Nt fragment from FOXO3TM used as dominant-negative (FOXO3-A32A253-Nt) (Charvet et al., 2003) , or the active FOXO3TM mutated in the DNA binding domain (FOXO3TM-H212R). Transfection of FOXO3TM induced a 2-fold increase in luciferase activity, whereas the transfection of FOXO3-A32A253-Nt had no impact ( Figure 4D ). To assess whether the 3 0 UTR region is involved for EOMES expression, an 81 bp fragment of the p3 0 UTR-E region containing the two putative FBSs was sub-cloned into the pEomes-luc vector (pEomes_p3 0 UTR-E_luc). Using this construct, we found a 6-fold increased luciferase activity in the presence of FOXO3TM, whereas the mutant FOXO3TM-H212R failed to affect luciferase activity, indicating that FOXO3 bound directly to the FBS in the p3 0 UTR-E_region of EOMES ( Figure 4E ). Altogether, these results show that FOXO3 binds to FBSs present in the 3 0 UTR region of EOMES and that EOMES is a direct transcriptional target gene of FOXO3.
We next assessed whether Eomes expression was also linked to GM-CSF and IFN-g secretion in CD4
+ T cells. Intracellular staining showed that the expression of Eomes was higher in GM-CSF + IFN-g + cells as compared to GM-CSF Figure 4F ). Moreover, when naive CD4
Log(FC Foxo3 Relative expression T cells purified from mice with a T cell-specific deletion of Eomes (Eomes fl/fl Cd4-cre) were stimulated in vitro with increased concentration of anti-CD3 mAbs, both GM-CSF and IFN-g secretion were reduced in Eomes fl/fl Cd4-cre + CD4 + T cells as compared to Eomes fl/fl Cd4-cre À cells ( Figure 4G ), whereas the proliferation and survival were similar (data not shown). Therefore, the decreased Eomes expression associated with Foxo3 deficiency might explain the defect GM-CSF and IFN-g secretion in Foxo3
À/À CD4 + T cells. To address this issue directly, we tested whether lentiviral-based overexpression of Eomes could overcome the defect in IFN-g and GM-CSF production. We showed that Eomes transduction of Foxo3-deficient T cells restored the expression of both IFN-g and GM-CSF ( Figures 4H and 4I ). This finding supports the notion that Foxo3 indirectly regulates Ifng and Csf2 in CD4 + T cells through the regulation of Eomes expression.
In addition, we address whether Eomes directly controls Ifng and Csf2 expression. We performed an in silico analysis and found six highly conserved noncoding sequences enriched in DNaseI hypersensitivity sites and putative transcription factor binding sites positioned downstream of the 3 0 UTR of CSF2. Next, luciferase reporter assays were performed by coupling these elements to the proximal CSF2 promoter. Using this technique, we were unable to demonstrate a direct regulation of CSF2 by EOMES ( Figure S5A ). In contrast, the same technique revealed that EOMES, but not FOXO3, directly transactivates the promoter of IFNG ( Figure S5B ). Moreover, we showed that Foxo3 was unable to transactivate the Ifng locus ( Figure S5C ). Altogether, these data support the concept that the EomesFoxo3 axis is required for the polarization of effector CD4 + T cells into IFN-g-and GM-CSF-producing cells.
Eomes Acts Independently of T-bet for GM-CSF Regulation in CD4
+ T Cells by CD4 + T cell might be Eomes dependent but T-bet independent ( Figure 5A ). In this regard, previous studies demonstrate that the first wave of IFN-g is T-bet independent and causes the autocrine induction of T-bet (Schulz et al., 2009) . Therefore, the decreased T-bet expression in Foxo3 À/À cells might be due to the decreased Eomes-dependent IFN-g secretion.
To test this hypothesis, WT and Foxo3 À/À CD4 + T cells were stimulated in the presence of neutralizing anti-IFNg monoclonal antibody (mAb) to prevent T-bet induction by IFN-g. Upon IFN-g neutralization, a clear reduction of T-bet expression was observed, leading to similar expression of T-bet in both WT and Foxo3 À/À CD4 + T cells ( Figure 5B ). These results establish that Foxo3 has no direct impact on T-bet expression and further indicate that decreased T-bet resulted from decreased IFN-g secretion by Foxo3
À/À CD4 + T cells. We also showed that the expression of Eomes was independent of the signaling pathway downstream of IFN-g since the expression of Eomes was not affected by blocking IFN-g ( Figure 5C ).
We next analyzed cytokine secretion in presence of blocking anti-IFN-g antibody. Although suppressing the IFN-g autocrine effect strongly impacted the production of IFN-g, it had no effect on GM-CSF production. Yet, GM-CSF secretion was diminished in Foxo3 À/À cells whereas T-bet expression remained unchanged ( Figures 5D and S5D) . These results further support the notion that the Foxo3-Eomes pathway, but not T-bet, is critical for GM-CSF regulation. Similar results were obtained in T cells overexpressing Eomes after lentiviral transduction. Under conditions in which the IFN-g was blocked and expression of T-bet was low, Eomes overexpression still resulted in increased IFN-g and GM-CSF expression ( Figures 5E and 5F) . These data further demonstrate that Eomes can act independently of T-bet to control IFN-g and GM-CSF secretion.
Foxo3 Controls the Severity to Neuroinflammation
We next addressed the in vivo relevance of the Eomes-Foxo3 pathway by assessing whether Foxo3 deficiency modifies the susceptibility to experimental autoimmune encephalomyelitis (EAE), a well-characterized mouse model for multiple sclerosis (MS). Hence, Foxo3 À/À female mice and their wild-type littermates were immunized with MOG 35-55 peptide emulsified in CFA. Although the incidence of EAE disease and the mean day of onset were similar, Foxo3 À/À mice developed a much less severe disease than their wild-type counterparts ( Figure 6A ). Comparable results were obtained when male mice were used, showing that there was no gender bias ( Figure S6A ). To assess whether this decreased EAE severity was the consequence of a bias in the TCR repertoire, Foxo3 À/À mice were crossed to 2D2 TCR transgenic mice in which the CD4 + T cell population expresses an I-A b -restricted TCR specific for the immune-dominant MOG 35-55 peptide (Bettelli et al., 2003) . Foxo3 deficiency in 2D2 mice also led to a reduction of disease severity ( Figure 6B À/À mice. Mice were next immunized and disease severity was evaluated. Both groups of mice developed EAE with similar incidence, kinetics, and severity ( Figure 6C ). These data point to a minimal role of Foxo3 in non-T cells during EAE development. Furthermore, EAE experiments were next conducted on genetically engineered mice harboring a T cell-specific deletion of Foxo3 (Foxo3 fl/fl -Cd4-cre). Foxo3 fl/fl -Cd4-cre + mice developed disease with a reduced incidence and severity as compared to Foxo3 fl/fl -Cd4-cre À control mice, demonstrating that Foxo3 controls the susceptibility to EAE in a T cell-intrinsic manner ( Figure 6D ). Altogether, these results reveal that Foxo3 expression in CD4 + T cells plays a critical role in the susceptibility to CNS inflammation.
Foxo3 Drives the Differentiation of Pathogenic IFN-g + and GM-CSF + CD4 + T Cells during EAE
We next assessed whether the outcome of EAE in Foxo3-deficient mice was accompanied by differences in polarization of both peripheral and CNS-infiltrating CD4 + T cells. In agreement with our results obtained in vitro, MOG-specific Foxo3-deficient CD4 + T cells produced lower amounts of the effector cytokines IFN-g and GM-CSF whereas the production of IL-17, TNF, and other cytokines was not affected (Figures 7A and S7A ). Intracellular staining was performed to identify which Th cell subset was impacted by Foxo3 deficiency. We observed a large decrease in the proportion of both IFN-g + GM-CSF À and IFN-g + GM-CSF to secrete IFN-g and GM-CSF ( Figures S7C-S7E ). The proportion of CNS-infiltrating Foxp3 + CD4 + T cells was not altered by Foxo3 deficiency ( Figure S7F ). As described in total Foxo3 À/À mice, MOG-specific CD4 + T cells from Foxo3 fl/fl -Cd4-cre + exhibited decreased secretion of IFN-g and GM-CSF whereas IL-17 secretion was unchanged ( Figure 7D) . Again, the frequency of Foxp3 Treg cells was unaltered in both periphery and CNS ( Figure 7E and S7G) . Altogether, these results reveal the T cell-intrinsic control of Foxo3 on encephalitogenic CD4 + T cell differentiation and susceptibility to CNS autoimmunity.
DISCUSSION
Up to now, the role of Foxo3 in CD4 + T cell has been unappreciated, mainly because of its low expression in lymphoid cells and also because of the dominant role of Foxo1. The present study showed that TCR engagement results in increased expression of Foxo3 in CD4 + T cells and that this increase correlates with TCR signaling strength. Moreover, this increased Foxo3 expression has a functional impact on CD4 + T cells. Foxo3 deletion in primary CD4 + T cells specifically impaired their ability to secrete IFN-g and GM-CSF. Importantly, microarray analyses showed that decreased expression of genes involved in the IFN-g pathway was not associated with global defect of CD4 + T cell activation or changes in expression of genes from Th2, Th17, or Treg cell programs, further demonstrating that Foxo3 plays a specific role in the polarization of pathogenic CD4 + T cells.
These results are consistent with our in vitro and in vivo results showing that, after anti-CD3 stimulation or immunization with MOG 35-55 peptide, CD4 + T cells from Foxo3 À/À mice showed a decreased production of IFN-g and GM-CSF whereas the ability of these cells to secrete IL-17, type 2 cytokines, or IL-10 was not affected. We therefore conclude that Foxo3 deficiency is not associated with a general defect in CD4 + T cell activation but rather impacts Th cell polarization by specifically disturbing the production of both IFN-g and GM-CSF. Several studies show that Foxo factors are crucial for Foxp3 Treg cell development and function (Kerdiles et al., 2010; Ouyang et al., 2010 Ouyang et al., , 2012 Analysis of the molecular mechanism underlying these phenotypes revealed that Foxo3 induces expression of the TF Eomes. We showed that Eomes expression is controlled by TCR signaling strength and correlates with the dynamics of Foxo3 expression in CD4 + T cells, supporting the notion that Foxo3 might regulate Eomes in CD4 + T cells. Eomes was indeed a direct target gene of Foxo3 in CD4 + T cells. Transactivation of Eomes by Foxo3 was dependent upon a 3 0 UTR distal region containing two FBSs and may correspond to an enhancer region. Accordingly, the analysis of Foxo3 genomewide binding profile showed that this TF acts as a transcriptional activator, regulating target gene expression through transcription initiation by binding preferentially to enhancer regions with increased conservation (Eijkelenboom et al., 2013a (Eijkelenboom et al., , 2013b .
In CD4 + T cells, most of the described roles for Eomes are redundant with T-bet (Steiner et al., 2011; Suto et al., 2006; Yang et al., 2008) . Here, we have provided information on the critical role of Eomes, independent of T-bet, in CD4 + T cell polarization. Overexpression of Eomes overcame the defect in IFN-g and GM-CSF production by Foxo3-deficient CD4 + T cells, supporting the notion that Eomes is involved in Ifng and Csf-2 regulation in CD4 + T cells. Moreover, under conditions in which T-bet upregulation was blocked, Eomes overexpression still resulted in increased IFN-g and GM-CSF expression. These results are in agreement with data showing that Eomes is responsible for the T bet-independent production of IFN-g in T-bet-deficient or GATA3-deficient CD4 + T cells (Yagi et al., 2010; Yang et al., 2008) . Therefore, the Foxo3-Eomes axis is part of the signaling events responsible for the first wave of IFN-g. As a consequence, decreased Eomes expression by Foxo3-deficient cells led to reduction of IFN-g and disrupted the positive feedback loop by which IFN-g supports T-bet expression. Indeed, our results demonstrated that neither Eomes nor Foxo3 were able to directly regulate T-bet expression. Moreover, inhibition of the IFN-g autocrine loop had no effect on GM-CSF secretion, further demonstrating that the Foxo3-Eomes pathway, but not T-bet, is critical for GM-CSF regulation (O'Connor et al., 2013) . Uncontrolled CD4 + T cell polarization may have pathological consequences and lead to autoimmune diseases. We showed that Foxo3 deficiency diminished disease severity and that this phenotype is T cell intrinsic and correlated with the reduced ability of Foxo3-deficient CD4 + T cells to differentiate into IFN-g-and GM-CSF-producing CD4 + T cells. IFN-g, IL-17, and GM-CSF are the main effector cytokines in the pathophysiology of both EAE and MS (Codarri et al., 2010; Goverman, 2009; Korn et al., 2009 ). In immunized Foxo3-deficient animals, the frequency of MOG-specific Th17 cells was unaffected, excluding the involvement of Th17 cells in the observed phenotype. Decreased IFN-g production by Foxo3-deficient CD4 + T cells may impact T cell distribution within the CNS. Indeed, Foxo3-deficient T cells migrated preferentially to the brain rather than spinal cord. These results are consistent with studies showing that the Th17-Th1 cell ratio of infiltrating T cells determines the topography of CNS inflammation (Goverman, 2009; Stromnes et al., 2008) . However, we can not exclude that Foxo3 might have a direct role in T cell migration and homing since microarray analysis showed that Foxo3-deficient CD4 + T cells exhibited increased expression of Klf2, S1pr1, and Sell and decreased expression of Ccr8. Perhaps most importantly, we showed that Foxo3 deficiency also impacted the ability of CD4 + T cell to produce GM-CSF, a key factor in the effector phase of EAE (McQualter et al., 2001; Ponomarev et al., 2007) . Both Th1 and Th17 cells can secrete GM-CSF during EAE (Codarri et al., 2011) . However, a recent study showed that GM-CSF + Th cells might represent a unique Th cell lineage distinct from that of Th1 and Th17 cells (Herndler-Brandstetter and Flavell, 2014; Sheng et al., 2014) . The factors regulating Csf2 expression remain to be defined (Croxford et al., 2015) . Here, we have shown that GM-CSF-producing CD4 + T cells exhibited high and sustained expression of Eomes and that low Eomes expression impaired the differentiation of GM-CSF-producing cells. These data suggest the implication of this TF in the gene program of GM-CSF-secreting CD4 + T cells. In agreement, recent transcriptomic studies showed that Eomes is among the genes that are specifically expressed by the GM-CSF + Th cell lineage (Sheng et al., 2014) . The role of this T-box transcription factor in CNS neuroinflammation has recently been demonstrated. Indeed, mice harboring a T cell-specific deletion of Eomes developed EAE with reduced severity, a similar phenotype as Foxo3-deficient mice (Raveney et al., 2015) . Moreover, EOMES has been identified as a susceptibility gene in MS (Parnell et al., 2014; Patsopoulos et al., 2011) . In addition, an increased proportion of Eomes + CD4 + T cells has been reported in patients with secondary progressive MS as compared to relapsing remitting MS or healthy controls and these cells accumulate in the CSF from MS patients, further supporting the role of this transcription factor in CNS inflammation in humans (Raveney et al., 2015) .
EXPERIMENTAL PROCEDURES Mice
Foxo3
À/À ), 2D2 (Bettelli et al., 2003) , Eomes
Cd4-cre , Foxo3 fl/fl Cd4-cre (Paik et al., 2007) , and C57BL/6 mice were maintained in the breeding facility of PreCREFRE (Toulouse UMS06) under SPF conditions. All animal procedures were conducted in accordance with institutional guidelines on Animal Experimentation and were under a French Ministry of Agriculture license. 
Experimental Autoimmune Encephalomyelitis
Microarray Gene Expression Study
Gene expression analysis was performed on purified naive CD4 + T cells from
Foxo3
À/À (n = 3-4) or WT (n = 4) littermate controls either unstimulated (T0) or stimulated with 2 mg/mL of anti-CD3 mAbs for 12 (T12) or 24 (T24) hours at the GeT facility (Gé noToul, Gé nopole Toulouse Midi-Pyré né es) using Agilent Sureprint G3 Mouse microarrays (8x60K, design 028005) according to the manufacturer's instructions.
Chromatin Immunoprecipitation CD4 + T cells were stimulated with anti-CD3 (2 mg/mL) and anti-CD28 (1 mg/mL) mAbs for 24 hr. Foxo3 ChIP experiments were performed using iDeal ChIPSeq Kit for Transcription Factors (Diagenode, C01010055) with some modifications. In brief, cells were fixed with 1% PFA during 15 min and then glycine (0.250 mM) was added. Cells were then lysed with manufacturer's buffers and sonicated with 15 cycles of 30 s ON/60 s OFF using a bioruptor pico. Sonicated chromatin was incubated overnight at 4 C either with 5 mg of anti-Foxo3 antibody (Santa Cruz cat# sc-11351X) or an IgG control. Chromatin was then washed and eluted using manufacturer's recommendations. For ChIP analysis, qPCR was performed using SyberGreen Master mix (Roche) on a 480 LightCycler in duplicate with primers listed in Table S1 . Percent of input was calculated using the following formula: 2^(adjusted INPUT-Ct (IP))3100 where adjusted INPUT = Ct INPUT -log2 (1).
Luciferase Assay HEK293T cells were co-transfected both with Eomes_Luc or pEomes_ p3 0 E_luc plasmids together with plasmids coding for different forms of FOXO3 (FOXO3TM, FOXO3TM-H212R, or FOXO3-A32A253-Nter) or with an empty vector using Genejuice (Novagen). Luciferase assays were performed with a dual luciferase assay kit (Promega, Dual-Luciferase Reporter Assay System, E1910) and all luciferase activities were normalized to the expression of the co-transfected Renilla luciferase.
Lentiviral Vector Transduction of Naive CD4 + T Cells
The gene encoding eomes was synthetized and fully sequenced by Life Technologies. The cDNA was then inserted into a pWPXLd-IRES-GFP backbone vector using BamHI and PmeI restriction sites to make the pWPXLD-Eomes-IRES-GPF vector. 5 3 10 6 naive Foxo3 À/À CD4 + T cells were activated with anti-CD3 (3 mg/mL) plus soluble anti-CD28 (2 mg/mL) and IL-2 (10 UI/mL) in p24-well plates coated overnight with 40 mg/mL of RetroNectin (TAKRA). 18 hr after activation, the medium was replaced by OptiMEM medium containing lentiviral particles (LV-EOMES or LV-GFP). Anti-CD28 and IL-2 were added (10 UI/mL and 2 mg/mL, respectively). Cells were then centrifuged (3,000 rpm) for 1 hr at 32 C and incubated overnight at 37 C. The next day, supernatant was replaced by complete RPMI medium supplemented with IL-2 (10 UI/mL) and anti-CD28 (2 mg/mL). 72 hr after transduction, infected cells were then activated with PMA plus ionomycin (0.5 mg/mL each) for 4 hr plus Golgiplug (1/1,000). Cells were then stained and analyzed by flow cytometry (FACS LSRII).
Statistical Analysis p values were determined by Mann-Whitney tests. p values < 0.05 were considered statistically significant (***p < 0.001, **p < 0.005, *p < 0.01). All error bars represent the SEM. For EAE clinical scores, p values were determined by two-way ANOVA (***p < 0.001, **p < 0.005, *p < 0.01).
ACCESSION NUMBERS
Microarray data and experimental details are available in the Gene Expression Omnibus (GEO) database (accession GSE86287). 
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